Farber’s Disease Market Trends Reshaping Industry Growth Through 2030
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Farber’s Disease Market Size Forecast: How Big Could The Market Get By 2030?
The farber’s disease market has shown significant expansion in recent years. Its value is expected to rise from $1.98 billion in 2025 to $2.1 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.9%. This past growth can be ascribed to several factors, including the identification of rare diseases, the availability of pediatric genetic testing, established supportive care protocols, increased hospital specialization, and dedicated research funding.
The farber’s disease market is anticipated to experience substantial expansion in the coming years. By 2030, this market is projected to reach $2.61 billion, exhibiting a compound annual growth rate (CAGR) of 5.6%. This anticipated growth during the forecast period is attributable to several factors, including developments in gene therapy pipelines, incentives for orphan drugs, initiatives for early diagnosis, establishment of rare disease registries, and sophisticated genetic tools. Key trends expected over the forecast period encompass a heightened emphasis on rare pediatric conditions, broadening gene therapy research, an increase in the adoption of supportive care, the emergence of multidisciplinary treatment strategies, and advancements in genetic diagnostics.
Get A Free Sample Report With In-Depth Market Insights:
Farber’s Disease Market Growth Momentum: What Factors Are Shaping Demand?
The increasing occurrence of rare genetic disorders is projected to fuel the expansion of the Farber’s disease market going forward. Rare genetic diseases are defined as inherited conditions stemming from DNA mutations that impact a very small segment of the population. The rising incidence of these disorders is attributed to enhanced diagnostic technologies, which allow for earlier and more precise identification of conditions that were previously undiagnosed or misdiagnosed. Farber’s disease plays a vital role in addressing this growing prevalence by serving as a framework for developing targeted therapies and advancing research in enzyme replacement treatments for ultra-rare conditions. For instance, in February 2023, the European Commission (EC), a Belgium-based government entity, reported that up to 36 million people in the European Union live with a rare disease; the EU is home to more than 6,000 distinct rare diseases, and approximately 80% of rare diseases have a genetic origin. Thus, the increasing prevalence of rare genetic diseases is driving the growth of the Farber’s disease market. Higher investment in clinical trials is anticipated to boost the Farber’s disease market moving forward. Clinical trials are research studies performed on humans to evaluate the safety, effectiveness, and results of medical interventions such as drugs, treatments, or devices. This surge in clinical trial investment is due to the growing demand for innovative treatments, which is driven by advancements in medical science, personalized medicine, and the urgent need to address unmet healthcare needs. Farber’s disease contributes by emphasizing the critical requirement for research into rare and underserved genetic disorders. For instance, in October 2024, Citeline, a US-based pharma intelligence solutions provider, stated that TrialTrove captured 9,959 Phase I–III clinical trials with a 2024 start date investigating at least one drug, representing a 9.4% increase from 2023. Therefore, the increasing investment in clinical trials is driving the growth of the Farber’s disease market.
Farber’s Disease Market Segment Analysis Spotlighting Growth Areas
The farber’s disease market covered in this report is segmented –
1) By Type Of Farber’s Disease: Classical Farber’s Disease, Non-Classical Farber’s Disease
2) By Treatment: Enzyme Replacement Therapy, Symptomatic Treatment, Gene Therapy, Bone Marrow Transplant, Supportive Care
3) By Clinical Symptoms: Joint Involvement And Deformities, Hearing Loss, Respiratory Distress, Dermatological Manifestations
4) By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users
Subsegments:
1) By Classical Farber’s Disease: Type 1 Severe Infantile Form, Type 2 Intermediate Childhood Form, Type 3 Juvenile-Onset Form
2) By Non-Classical Farber’s Disease: Type 4 Neurological Predominant Form, Type 5 Visceral Predominant Form, Type 6 Cardiopulmonary Involvement Form
Farber’s Disease Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the farber’s disease market are National Institutes of Health (NIH), U.S. National Institute of Neurological Disorders and Stroke (NINDS), Mount Sinai Icahn School of Medicine, Cincinnati Children’s Hospital Medical Center, University of Pennsylvania Gene Therapy Program, Seattle Children’s Research Institute, Genethon (AFM-Téléthon), Sarepta Therapeutics Inc., REGENXBIO Inc., Abeona Therapeutics Inc., Rocket Pharmaceuticals Inc., Passage Bio Inc., Spark Therapeutics Inc., Takeda Rare Disease Research, Orchard Therapeutics plc, Avrobio Inc., bluebird bio Inc., JCR Pharmaceuticals Co. Ltd., Protalix BioTherapeutics Inc., Ultragenyx Pharmaceutical Inc., BioMarin Pharmaceutical Inc., Amicus Therapeutics Inc.
View The Full Farber’s Disease Market Report:
Farber’s Disease Market Global Footprint: Which Region Leads The Industry?
North America was the largest region in the farber’s disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the farber’s disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
